Question

A Merck representative visits your office and tells you that Fosamax (alendronate) will decrease the incidence of repeat hip fracture by 50% over 3 years. That excites you because you have 20 elderly women and 5 elderly men who already have fractured one hip in your practice. You locate the study by Black in Lancet (1996) and find out that fracture occurs in 2.2% of placebo patients and 1.1% of patients on Fosamax. 1. What is the EER for this scenario? Answer as a percent.

Answer 1

EER for this scenario will be

Given 1.1% fracture (Fosamax)

total elderly populatio26÷1.1÷100

=0.22% is the ERR for this type of scenarios